central nervous system lupus vasculitis

Summary

Summary: Central nervous system vasculitis that is associated with SYSTEMIC LUPUS ERYTHEMATOSUS. Clinical manifestations may include DEMENTIA; SEIZURES; CRANIAL NERVE DISEASES; HEMIPARESIS; BLINDNESS; DYSPHASIA; and other neurological disorders.

Top Publications

  1. Appenzeller S, Pike G, Clarke A. Magnetic resonance imaging in the evaluation of central nervous system manifestations in systemic lupus erythematosus. Clin Rev Allergy Immunol. 2008;34:361-6 pubmed
    ..We will describe MRI findings in SLE patients and discuss the usefulness of different MRI techniques in evaluating acute and chronic CNS manifestations...
  2. Petri M, Naqibuddin M, Carson K, Wallace D, Weisman M, Holliday S, et al. Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus. J Rheumatol. 2008;35:2348-54 pubmed
    ..We wished to determine the prevalence of cerebral atrophy and focal lesions in a cohort of patients with newly diagnosed systemic lupus erythematosus (SLE) and the association of these brain abnormalities with clinical characteristics...
  3. Sanna G, Bertolaccini M, Mathieu A. Central nervous system lupus: a clinical approach to therapy. Lupus. 2003;12:935-42 pubmed
    ..Anticoagulation is warranted in patients with thrombotic disease, particularly in those with the antiphospholipid syndrome (APS). This article reviews the clinical approach to therapy in patients with CNS lupus...
  4. Castellino G, Govoni M, Giacuzzo S, Trotta F. Optimizing clinical monitoring of central nervous system involvement in SLE. Autoimmun Rev. 2008;7:297-304 pubmed publisher
  5. Csepany T, Bereczki D, Kollar J, Sikula J, Kiss E, Csiba L. MRI findings in central nervous system systemic lupus erythematosus are associated with immunoserological parameters and hypertension. J Neurol. 2003;250:1348-54 pubmed
  6. Karassa F, Afeltra A, Ambrozic A, Chang D, De Keyser F, Doria A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum. 2006;54:312-24 pubmed
  7. Kozora E, Ellison M, West S. Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Rheum. 2004;51:810-8 pubmed
    ..To examine the reliability and validity of the proposed American College of Rheumatology (ACR) neuropsychological battery for patients with systemic lupus erythematosus (SLE)...
  8. Steens S, Admiraal Behloul F, Bosma G, Steup Beekman G, Olofsen H, le Cessie S, et al. Selective gray matter damage in neuropsychiatric lupus. Arthritis Rheum. 2004;50:2877-81 pubmed
  9. Sato E, Iikuni N, Yoshio T, Minota S, Kamatani N, Okamoto H. Soluble fractalkine in the cerebrospinal fluid of patients with neuropsychiatric lupus. Ann Rheum Dis. 2006;65:1257-9 pubmed

More Information

Publications62

  1. Oku K, Atsumi T, Furukawa S, Horita T, Sakai Y, Jodo S, et al. Cerebral imaging by magnetic resonance imaging and single photon emission computed tomography in systemic lupus erythematosus with central nervous system involvement. Rheumatology (Oxford). 2003;42:773-7 pubmed
    ..To assess the significance of magnetic resonance imaging (MRI) and single photon emission computed tomography (SPECT) abnormalities in patients with systemic lupus erythematosus (SLE)...
  2. Dellalibera Joviliano R, Dos Reis M, Cunha F, Donadi E. Kinins and cytokines in plasma and cerebrospinal fluid of patients with neuropsychiatric lupus. J Rheumatol. 2003;30:485-92 pubmed
    ..To evaluate the kinin system components and selected cytokines in plasma and cerebrospinal fluid (CSF) of patients with neuropsychiatric lupus (NPL)...
  3. Greenwood D, Gitlits V, Alderuccio F, Sentry J, Toh B. Autoantibodies in neuropsychiatric lupus. Autoimmunity. 2002;35:79-86 pubmed
    ..We conclude that the search for specific antibody marker(s) that can be applied for the routine laboratory diagnosis for neuropsychiatric lupus remains elusive...
  4. Jennekens F, Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology (Oxford). 2002;41:605-18 pubmed
    ..To establish the central nervous system (CNS) manifestations of systemic lupus erythematosus (SLE) as described in the literature and to compare the results with two previously published classifications...
  5. Zandman Goddard G, Chapman J, Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum. 2007;36:297-315 pubmed
  6. Afeltra A, Garzia P, Mitterhofer A, Vadacca M, Galluzzo S, Del Porto F, et al. Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. Neurology. 2003;61:108-10 pubmed
    ..Sixty-one consecutive SLE patients were studied. Neuropsychiatric manifestations consistent with the diagnosis of NPSLE occurred in 44 (72%). Patients with NPSLE showed significantly higher levels of anticardiolipin antibodies...
  7. Hirohata S, Kanai Y, Mitsuo A, Tokano Y, Hashimoto H. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol. 2009;28:1319-23 pubmed publisher
    ..3%, respectively, at the cut-off value of 4.3 pg/ml. These results indicate that CSF IL-6 might be an effective measure in diagnosing LP, although exclusion of infectious meningoencephalitis and cerebrovascular accident is necessary...
  8. Yoshio T, Hirata D, Onda K, Nara H, Minota S. Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus. J Rheumatol. 2005;32:34-9 pubmed
  9. Senecal J, Raymond Y. The pathogenesis of neuropsychiatric manifestations in systemic lupus erythematosus: a disease in search of autoantibodies, or autoantibodies in search of a disease?. J Rheumatol. 2004;31:2093-8 pubmed
  10. Reichlin M. Ribosomal P antibodies and CNS lupus. Lupus. 2003;12:916-8 pubmed
    ..Continued study will inform us of the relative contribution of these autoantibodies to CNS disease in SLE patients...
  11. Svenungsson E, Andersson M, Brundin L, van Vollenhoven R, Khademi M, Tarkowski A, et al. Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann Rheum Dis. 2001;60:372-9 pubmed
    ..To investigate systemic and intrathecal production of proinflammatory cytokines in relation to cerebrospinal fluid (CSF) nitric oxide (NO) release in patients with neuropsychiatric lupus erythematosus (NPLE)...
  12. Hanly J, Robichaud J, Fisk J. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J Rheumatol. 2006;33:1553-8 pubmed
    ..To determine the prevalence of circulating anti-NR2 antibodies and their association with neuropsychiatric systemic lupus erythematosus (NP-SLE), particularly cognitive function, in women with SLE...
  13. Hanly J, McCurdy G, Fougere L, Douglas J, Thompson K. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol. 2004;31:2156-62 pubmed
  14. Williams R, Sugiura K, Tan E. Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2004;50:1239-47 pubmed
    ..We undertook this study to examine the presence of autoantibodies to MAP-2 in neuropsychiatric systemic lupus erythematosus (NPSLE)...
  15. Peterson P, Howe F, Clark C, Axford J. Quantitative magnetic resonance imaging in neuropsychiatric systemic lupus erythematosus. Lupus. 2003;12:897-902 pubmed
    ..This article reviews the current literature on the use of these techniques and their possible future role as diagnostic tools in NPSLE...
  16. Jonsen A, Bengtsson A, Nived O, Ryberg B, Truedsson L, Ronnblom L, et al. The heterogeneity of neuropsychiatric systemic lupus erythematosus is reflected in lack of association with cerebrospinal fluid cytokine profiles. Lupus. 2003;12:846-50 pubmed
  17. Abbott N, Mendonça L, Dolman D. The blood-brain barrier in systemic lupus erythematosus. Lupus. 2003;12:908-15 pubmed
    ..Both can result in barrier breakdown. Neurological syndromes could then be secondary to damage to the BBB. The implications for treatment of NPSLE are discussed...
  18. Eber T, Chapman J, Shoenfeld Y. Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality?. Lupus. 2005;14:571-5 pubmed
    ..This review summarizes the recent studies about relationship between anti-P antibodies and psychiatric manifestation of SLE...
  19. Bosma G, Middelkoop H, Rood M, Bollen E, Huizinga T, van Buchem M. Association of global brain damage and clinical functioning in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2002;46:2665-72 pubmed
  20. Hughes M, Sundgren P, Fan X, Foerster B, Nan B, Welsh R, et al. Diffusion tensor imaging in patients with acute onset of neuropsychiatric systemic lupus erythematosus: a prospective study of apparent diffusion coefficient, fractional anisotropy values, and eigenvalues in different regions of the brain. Acta Radiol. 2007;48:213-22 pubmed
    ..To investigate whether apparent diffusion coefficient (ADC), fractional anisotropy (FA), and eigenvalues in neuropsychiatric systemic lupus erythematosus (NPSLE) patients differ from those of healthy controls...
  21. Trysberg E, Nylen K, Rosengren L, Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum. 2003;48:2881-7 pubmed
  22. Roldan C, Gelgand E, Qualls C, Sibbitt W. Valvular heart disease is associated with nonfocal neuropsychiatric systemic lupus erythematosus. J Clin Rheumatol. 2006;12:3-10 pubmed
    ..Valvular heart disease (VHD) is currently not a causal consideration of nonfocal NPSLE...
  23. Hanly J, Harrison M. Management of neuropsychiatric lupus. Best Pract Res Clin Rheumatol. 2005;19:799-821 pubmed
    ..In the absence of controlled studies, the use of symptomatic therapies, immunosuppressives, anticoagulants and non-pharmacologic interventions is supported by case series and clinical experience...
  24. Yajima N, Kasama T, Isozaki T, Odai T, Matsunawa M, Negishi M, et al. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum. 2005;52:1670-5 pubmed
  25. Hanly J. Neuropsychiatric lupus. Rheum Dis Clin North Am. 2005;31:273-98, vi pubmed
    ..Treatment remains largely empiric in the absence of controlled studies, and current strategies include the use of immunosuppressive therapies, appropriate symptomatic interventions, and the treatment of non-SLE factors...
  26. Graham J, Jan W. MRI and the brain in systemic lupus erythematosus. Lupus. 2003;12:891-6 pubmed
    ..We describe the MRI techniques used in CNS imaging and the pattern of presentation in SLE...
  27. Zhang L, Harrison M, Heier L, Zimmerman R, Ravdin L, Lockshin M, et al. Diffusion changes in patients with systemic lupus erythematosus. Magn Reson Imaging. 2007;25:399-405 pubmed
    ..Routine magnetic resonance imaging (MRI) findings are often nonspecific or negative. In this study, we explored the use of diffusion tensor imaging in assisting with the diagnosis of SLE...
  28. Kowal C, DeGiorgio L, Nakaoka T, Hetherington H, Huerta P, Diamond B, et al. Cognition and immunity; antibody impairs memory. Immunity. 2004;21:179-88 pubmed
    ..Furthermore, NMDA receptor antagonists prevent antibody-mediated damage and may constitute a new approach to therapy in SLE...
  29. Jennekens F, Kater L. The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation. Rheumatology (Oxford). 2002;41:619-30 pubmed
    ..To identify the pathogenetic mechanisms of central nervous system (CNS) syndromes of systemic lupus erythematosus (SLE) as described in the literature...
  30. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology. 2001;57:496-500 pubmed
  31. Okamoto H, Iikuni N, Kamitsuji S, Yoshio T, Minota S, Kamatani N. IP-10/MCP-1 ratio in CSF is an useful diagnostic marker of neuropsychiatric lupus patients. Rheumatology (Oxford). 2006;45:232-4 pubmed
  32. Yoshio T, Onda K, Nara H, Minota S. Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2006;54:675-8 pubmed
  33. Omdal R. Some controversies of neuropsychiatric systemic lupus erythematosus. Scand J Rheumatol. 2002;31:192-7 pubmed
    ..Some of the controversial issues on these matters are discussed in the article...
  34. Nived O, Sturfelt G, Liang M, De Pablo P. The ACR nomenclature for CNS lupus revisited. Lupus. 2003;12:872-6 pubmed
    ..The acquisition of normative data for ethnic, age and sex stratification would extend their usefulness...
  35. Appenzeller S, Rondina J, Li L, Costallat L, Cendes F. Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis Rheum. 2005;52:2783-9 pubmed
  36. Sanchez Guerrero J, Aranow C, Mackay M, Volpe B, Diamond B. Neuropsychiatric systemic lupus erythematosus reconsidered. Nat Clin Pract Rheumatol. 2008;4:112-3 pubmed publisher
  37. Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology (Oxford). 2004;43:1555-60 pubmed
    ..To identify factors predictive of significant neuropsychiatric (NP) damage in systemic lupus erythematosus (SLE)...
  38. Fragoso Loyo H, Richaud Patin Y, Orozco Narváez A, Dávila Maldonado L, Atisha Fregoso Y, Llorente L, et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum. 2007;56:1242-50 pubmed
    ..To define the cytokine and chemokine profile in cerebrospinal fluid (CSF) from patients with neuropsychiatric systemic lupus erythematosus (NPSLE)...
  39. Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66:470-5 pubmed
    ..A standard treatment for NPSLE is not available. This report describes the clinical and laboratory tests of 10 patients with NPSLE before and after rituximab treatment, including changes in lymphocyte phenotypes...
  40. Sanna G, Bertolaccini M, Cuadrado M, Laing H, Khamashta M, Mathieu A, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol. 2003;30:985-92 pubmed
    ..Neuropsychometric testing was applied by a neuropsychologist. Univariate and multivariate statistical analyses were applied to evaluate the association bewteen NP manifestations, magnetic resonance imaging (MRI) abnormalities, and aPL...
  41. Sastre Garriga J, Montalban X. APS and the brain. Lupus. 2003;12:877-82 pubmed
  42. Meroni P, Tincani A, Sepp N, Raschi E, Testoni C, Corsini E, et al. Endothelium and the brain in CNS lupus. Lupus. 2003;12:919-28 pubmed
  43. Huizinga T, Steens S, van Buchem M. Imaging modalities in central nervous system systemic lupus erythematosus. Curr Opin Rheumatol. 2001;13:383-8 pubmed
  44. Bosma G, Steens S, Petropoulos H, Admiraal Behloul F, van den Haak A, Doornbos J, et al. Multisequence magnetic resonance imaging study of neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2004;50:3195-202 pubmed
  45. Denburg S, Denburg J. Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus. Lupus. 2003;12:883-90 pubmed
    ..To date, the most robust findings have emerged in relation to antiphospholipid antibodies, which carry with them important therapeutic implications...
  46. Gao H, Sanders E, Tieng A, Putterman C. Sex and autoantibody titers determine the development of neuropsychiatric manifestations in lupus-prone mice. J Neuroimmunol. 2010;229:112-22 pubmed publisher
    ..Our results are consistent with a primary role of autoantibodies in the pathogenesis of early neuropsychiatric deficits in this lupus model, which translate into gender-based differences in clinical phenotype...
  47. Sun X, Shi J, Han L, Su Y, Li Z. Anti-histones antibodies in systemic lupus erythematosus: prevalence and frequency in neuropsychiatric lupus. J Clin Lab Anal. 2008;22:271-7 pubmed publisher
    ..6-96.4% for SLE. The anti-histone antibody markers are prevalent in approximately 50% of NPSLE. Furthermore, there was a strong correlation with SLE disease activity index and levels of antibodies to histones and H1...
  48. Sibbitt W, Brooks W, Kornfeld M, Hart B, Bankhurst A, Roldan C. Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus. Semin Arthritis Rheum. 2010;40:32-52 pubmed publisher
    ..Magnetic resonance imaging (MRI) often demonstrates brain lesions in neuropsychiatric systemic lupus erythematosus (NPSLE). The present study compared postmortem histopathology with premortem MRI in NPSLE...
  49. Von Feldt J. Atherosclerosis and central nervous system involvement in systemic lupus erythematosus. J Clin Rheumatol. 2007;13:179-80 pubmed
  50. Appenzeller S, Amorim B, Ramos C, Rio P, de C Etchebehere E, Camargo E, et al. Voxel-based morphometry of brain SPECT can detect the presence of active central nervous system involvement in systemic lupus erythematosus. Rheumatology (Oxford). 2007;46:467-72 pubmed
  51. Dall era M, Cardarelli P, Preston B, Witte A, Davis J. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis. 2005;64:1692-7 pubmed
    ..Previous clinical studies in humans and murine models suggest that type I interferons (IFNs) are important for the initiation and potentiation of SLE activity...
  52. Shoenfeld Y. The diversity of autoantibodies to P-ribosomal: the infectious-autoimmunity plot. J Mol Med (Berl). 2007;85:907-9 pubmed
  53. Hanly J. Neuropsychiatric lupus. Curr Rheumatol Rep. 2001;3:205-12 pubmed
    ..Multicenter initiatives are required to address important issues on prognosis and management...